Previous close | 10,914.00 |
Open | 10,914.00 |
Bid | 10,750.00 x 0 |
Ask | 11,380.00 x 0 |
Day's range | 10,764.00 - 10,954.00 |
52-week range | 9,461.00 - 12,348.00 |
Volume | |
Avg. volume | 2,896,782 |
Market cap | 169.688B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 35.77 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.28 (2.09%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.